Molecular Biology

Welcome to the Aqeilan Lab at the Cyprus Cancer Research Institute (CCRI). Led by Professor Rami Aqeilan, our lab is dedicated to unraveling the complex molecular mechanisms underlying cancer. Our goal is to uncover the basic mechanisms and to translate this knowledge into innovative strategies for cancer diagnosis, treatment, and prevention, ultimately improving patient outcomes.

Molecular Biology

Welcome to the Aqeilan Lab at the Cyprus Cancer Research Institute (CCRI). Led by Professor Rami Aqeilan, our lab is dedicated to unraveling the complex molecular mechanisms underlying cancer. Our goal is to uncover the basic mechanisms and to translate this knowledge into innovative strategies for cancer diagnosis, treatment, and prevention, ultimately improving patient outcomes.

Professor Rami Aqeilan was appointed as Scientific Director of the Institute, effective 1 November 2023.

Prof. Rami Aqeilan is concurrently the Head of the Institute for Medical Research Israel-Canada (IMRIC) at the Faculty of Medicine of the Hebrew University of Jerusalem and Professor of Immunology and Cancer Research  at the Lautenberg Center for Immunology and Cancer Research.

At the Aqeilan Lab, our primary research interest lies in the intricate landscape of DNA double-strand breaks (DSBs) and their critical role in cancer development and progression. DNA DSBs are among the most severe forms of DNA damage, and their precise repair is crucial for maintaining genomic integrity and avoiding genomic instability. When this repair process is compromised, it can lead to the accumulation of mutations and the initiation of cancer. 

Role of Tumor Suppressor Gene Products of Common Fragile Sites in Human Diseases
Common fragile sites (CFSs) are large chromosomal regions identified by conventional cytogenetics as sequences prone to breakage in cells subjected to replication stress. The interest in CFSs stems from their key role in DNA damage, resulting in chromosomal rearrangements. The instability of CFSs was correlated with genome instability in precancerous lesions and during tumor progression. Two opposing views dominate the discussion regarding the role of CFSs. One school of thought suggested that genomic instability during cancer progression causes collateral damage to genes residing within CFSs, such as WWOX and FHIT. These genes are proposed to be unselected ‘‘passenger’’ mutations. The counter argument is that deletions and other genomic alterations in CFSs occur early in cancer development. Cancer cells with deletions in genes that span CFSs are then selectively expanded due to loss of tumor suppressor functions such as protection of genome stability, coordination of cell cycle or apoptosis.

Recent observations from our lab clearly suggest that gene products of CFSs play driver roles in cancer transformation. Furthermore, accumulating evidence links some of these products with metabolic diseases and neuropathy. Investigating the role of these gene products in human diseases is a major interest of our lab work. The ultimate goal of our research is hence to discover the genes and to elucidate the pathways that represent targets for the development of rational, specific and effective therapeutic approaches.

Research Team Members

Elena Christofidou

Postdoctoral Scientist

Maria Koumouri

Research Direction

Kostas Koufaris

Postdoctoral Scientist

Panayiotis Kouis

Research Assistant

Research Projects

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

We are dedicated to creating a comprehensive map of DNA double-strand breaks, employing state-of-the-art genomic technologies and innovative bioinformatics approaches. By understanding the when, where, and how DSBs occur and are repaired, we aim to gain significant insights into their contribution to cancer biology.

A cornerstone of our research is to identify and understand the vulnerabilities introduced by DSBs in cancer cells. These vulnerabilities represent potential therapeutic targets that could be exploited to selectively kill cancer cells without harming normal cells.

Leveraging the vulnerabilities identified, our goal is to develop innovative therapeutic strategies that target the unique dependencies of cancer cells on certain DNA repair pathways. This includes the design of novel drugs and gene therapies that can enhance the efficacy of existing treatments and overcome resistance mechanisms.

Our research work entails use of murine and human cancer specimens, models of genetic engineered mouse models (GEMMs), patient-derived xenografts (PDXs) and tumor organoids. We have a particular interest in studying pancreatic cancer, lung cancer and  pediatric sarcomas.

Through our research, the Aqeilan Lab aims to push the boundaries of our understanding of the molecular mechanisms of cancer, with the ultimate goal of uncovering new pathways for targeted cancer therapy. Our work not only contributes to the scientific understanding of DNA damage and repair but also paves the way for the development of more precise and personalized cancer treatments.

Publications

  • Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A 2007, 104(10): 3949-3954.
  • Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, Palumbo T, et al. The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem 2008, 283(31): 21629-21639.
  • Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008, 105(35): 12885-12890.
  • Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010, 17(2): 215-220.
  • Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, et al. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 2010, 70(13): 5577-5586.
  • Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18(4): 367-381.
  • Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, et al. Wwox inactivation enhances mammary tumorigenesis. Oncogene 2011, 30(36): 3900-3906.
  • Del Mare S, Kurek KC, Stein GS, Lian JB, Aqeilan RI. Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res 2011, 1(5): 585-594.
  • Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 2012, 72(7): 1865-1877.
  • Abu-Odeh M, Bar-Mag T, Huang H, Kim T, Salah Z, Abdeen SK, et al. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J Biol Chem 2014, 289(13): 8865-8880.
  • Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI. WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A 2014, 111(44): E4716-4725.
  • Abu-Remaileh M, Aqeilan RI. Tumor suppressor WWOX regulates glucose metabolism via HIF1alpha modulation. Cell Death Differ 2014, 21(11): 1805-1814.
  • Suh SS, Yoo JY, Cui R, Kaur B, Huebner K, Lee TK, et al. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs. PLoS Genet 2014, 10(10): e1004652.
  • Abu-Remaileh M, Joy-Dodson E, Schueler-Furman O, Aqeilan RI. Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells. J Biol Chem 2015, 290(52): 30728-30735.
  • Del Mare S, Husanie H, Iancu O, Abu-Odeh M, Evangelou K, Lovat F, et al. WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma. Cancer Res 2016, 76(20): 6107-6117.
  • Hazan I, Hofmann TG, Aqeilan RI. Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet 2016, 12(12): e1006436.
  • Abu-Remaileh M, Khalaileh A, Pikarsky E, Aqeilan RI. WWOX controls hepatic HIF1alpha to suppress hepatocyte proliferation and neoplasia. Cell Death Dis 2018, 9(5): 511.
  • Abu-Remaileh M, Abu-Remaileh M, Akkawi R, Knani I, Udi S, Pacold ME, Tam J, Aqeilan RI. WWOX somatic ablation in skeletal muscles alters glucose metabolism. Mol Metab. 2019 Apr;22:132-140.
  • Khawaled S, Suh SS, Abdeen SK, Monin J, Distefano R, Nigita G, Croce CM, Aqeilan RI. WWOX Inhibits Metastasis of Triple-Negative Breast Cancer Cells via Modulation of miRNAs. Cancer Res. 2019 Apr 15;79(8):1784-1798.
  • Commentary by Sharma, P.: Quest for Tangible Biomarkers for Triple-Negative Breast Cancer. [Cancer Res. 2019]

Join Us

We are always looking for talented and motivated researchers and investigators to join our team. If you are passionate about making a difference in the world of cancer research, explore our current openings for postdoctoral researchers, graduate students, and research technicians. Learn more about how you can contribute to our mission.

Contact

For more information, collaboration inquiries, or to discuss potential research opportunities, please contact us at: rami.aqeilan@ccri.org.cy

Professor Rami Aqeilan, PhD; Scientific Director and Principal Investigator @ Cyprus Cancer Research Institute (CCRI)